At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 60 enrolled
Drug / intervention
tandutinib +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Feasibility Assessment and a Phase I/II Trial of MLN518 for Treatment of Patients With Recurrent Glioblastoma
In Brief
A Phase 2 clinical trial evaluating conventional surgery, tandutinib, and 2 other interventions for Adult Brain Tumor and 4 related conditions. Completed, enrolled 60 participants across 9 sites.
Detailed Summary
This phase I/II trial is studying the side effects and best dose of tandutinib and to see how well it works in treating patients with recurrent or progressive glioblastoma.Tandutinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdult Brain Tumor, Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Recurrent Adult Brain Tumor
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedSep 2006
Enrollment StartJan 2007
Primary CompletionSep 2012
Study CompletionJun 2013
TodayJul 2026
First PostedSep 21, 2006
Enrollment StartJan 1, 2007
Primary CompletionSep 1, 2012
Study CompletionJun 1, 2013
TodayJul 2, 2026
Enrollment to primary: 5.7 yearsPosted 19.8 years ago
Interventions
conventional surgeryprocedure
Undergo surgery
tandutinibdrug
Given orally
pharmacological studyother
Correlative studies
Tissue samplesother
Correlative studies